Business
Interim Results
Interim Results.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 4354Q Futura Medical PLC 12 September 2017 \n\n\n\n\n\nFor immediate release\n\n\n12 September 2017\n\n\n\n\n \n \nFutura Medical plc\n(\"Futura\" or \"the Company\")\n \nInterim Results for the six months 30 June 2017\n \nFutura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce its interim results for the six months ended 30 June 2017.\n \nHighlights\n \nMED2002: Eroxon® - Treatment for erectile dysfunction (\"ED\")\n \n· Key meetings with US and UK regulators in H1 2017 on the further clinical development of MED2002 following breakthrough clinical results in H2 2016\n\n· Pharmacokinetic study to begin in Q4 2017 with the results informing a large-scale Phase III study to begin in H1 2018 \n· Out-licensing discussions are ongoing\n\nCSD500: Erectogenic condom\n \n· Successful product launch in the Middle East\n\n· Regulatory approval of additional brand names and packaging, enabling launch in several EU countries\n\n· Strategic consideration currently being given to commercialisation options for the countries covered by the Church & Dwight agreement, notice of termination of which was received in August 2017 \nPain relief products TPR100 (diclofenac) and TIB200 (ibuprofen)\n \n· First out-licensing agreement signed in January 2017 for TPR100 in the UK\n\n· UK regulatory submission for TPR100 targeted for Q1 2018\n\n· Ongoing out-licensing discussions for TIB200 and TPR100 outside of the UK\n \nFinancial\n \n· Net loss of £1.60 million in the period (H1 2016: net loss £1.89 million), reflecting planned reduction in R&D expenditure in preparation for MED clinical programme commencing in H2 2017\n \n· Cash resources of £10.12 million at 30 June 2017 (30 June 2016: £2.90 million)\n\n \nJames Barder, Futura's Chief Ex...